Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.

Nguyen TH, Tan A, Santos L, Ngo D, Edwards GA, Porter CJ, Prestidge CA, Boyd BJ.

J Control Release. 2013 Apr 10;167(1):85-91. doi: 10.1016/j.jconrel.2013.01.012. Epub 2013 Jan 23.

PMID:
23353808
[PubMed - indexed for MEDLINE]
2.

Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.

Tan A, Davey AK, Prestidge CA.

Pharm Res. 2011 Sep;28(9):2273-87. doi: 10.1007/s11095-011-0458-x. Epub 2011 May 11.

PMID:
21560021
[PubMed - indexed for MEDLINE]
3.

Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.

Tan A, Simovic S, Davey AK, Rades T, Prestidge CA.

J Control Release. 2009 Feb 20;134(1):62-70. doi: 10.1016/j.jconrel.2008.10.014. Epub 2008 Oct 30.

PMID:
19013488
[PubMed - indexed for MEDLINE]
4.

Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.

Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S.

J Pharm Pharm Sci. 2010;13(4):589-606.

PMID:
21486533
[PubMed - indexed for MEDLINE]
Free Article
5.

Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.

Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF.

J Pharm Sci. 2007 Oct;96(10):2686-702.

PMID:
17518357
[PubMed - indexed for MEDLINE]
6.

Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.

Morgen M, Bloom C, Beyerinck R, Bello A, Song W, Wilkinson K, Steenwyk R, Shamblin S.

Pharm Res. 2012 Feb;29(2):427-40. doi: 10.1007/s11095-011-0558-7. Epub 2011 Aug 24.

PMID:
21863477
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.

Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA.

Mol Pharm. 2010 Apr 5;7(2):522-32. doi: 10.1021/mp9002442.

PMID:
20063867
[PubMed - indexed for MEDLINE]
8.

Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.

Ghorab DM, Amin MM, Khowessah OM, Tadros MI.

Drug Deliv. 2011 Sep-Oct;18(7):523-35. doi: 10.3109/10717544.2011.595841. Epub 2011 Jul 28.

PMID:
21793779
[PubMed - indexed for MEDLINE]
9.

Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.

Nasr M.

AAPS PharmSciTech. 2013 Jun;14(2):719-26. doi: 10.1208/s12249-013-9957-x. Epub 2013 Mar 30.

PMID:
23543607
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Effect of eye pigmentation on transscleral drug delivery.

Cheruvu NP, Amrite AC, Kompella UB.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):333-41. doi: 10.1167/iovs.07-0214.

PMID:
18172110
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.

Yasmin R, Tan A, Bremmell KE, Prestidge CA.

J Pharm Sci. 2014 Sep;103(9):2950-9. doi: 10.1002/jps.23914. Epub 2014 Mar 1.

PMID:
24585389
[PubMed - in process]
12.

Impact of Solidification on the Performance of Lipid-based Colloidal Carriers: Oil-Based Versus Self-Emulsifying Systems.

Alinaghi A, Tan A, Rao S, Prestidge CA.

Curr Drug Deliv. 2014 Jul 16. [Epub ahead of print]

PMID:
25030115
[PubMed - as supplied by publisher]
13.

A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.

Boyd BJ, Khoo SM, Whittaker DV, Davey G, Porter CJ.

Int J Pharm. 2007 Aug 1;340(1-2):52-60. Epub 2007 Mar 24.

PMID:
17467935
[PubMed - indexed for MEDLINE]
14.

Influence of polymers on the bioavailability of microencapsulated celecoxib.

Homar M, Ubrich N, El Ghazouani F, Kristl J, Kerc J, Maincent P.

J Microencapsul. 2007 Nov;24(7):621-33.

PMID:
17763056
[PubMed - indexed for MEDLINE]
15.

Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption.

Tan A, Martin A, Nguyen TH, Boyd BJ, Prestidge CA.

Angew Chem Int Ed Engl. 2012 May 29;51(22):5475-9. doi: 10.1002/anie.201200409. Epub 2012 Apr 13. No abstract available.

PMID:
22505292
[PubMed - indexed for MEDLINE]
16.

Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.

Sek L, Boyd BJ, Charman WN, Porter CJ.

J Pharm Pharmacol. 2006 Jun;58(6):809-20.

PMID:
16734982
[PubMed - indexed for MEDLINE]
17.

Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.

Zhao P, Jiang H, Jiang T, Zhi Z, Wu C, Sun C, Zhang J, Wang S.

Eur J Pharm Sci. 2012 Apr 11;45(5):639-47. doi: 10.1016/j.ejps.2012.01.003. Epub 2012 Jan 11.

PMID:
22251657
[PubMed - indexed for MEDLINE]
18.

An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles.

Simovic S, Hui H, Song Y, Davey AK, Rades T, Prestidge CA.

J Control Release. 2010 May 10;143(3):367-73. doi: 10.1016/j.jconrel.2010.01.008. Epub 2010 Jan 14.

PMID:
20079390
[PubMed - indexed for MEDLINE]
19.

Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation.

Song WH, Park JH, Yeom DW, Ahn BK, Lee KM, Lee SG, Woo HS, Choi YW.

Arch Pharm Res. 2013 Jan;36(1):69-78. doi: 10.1007/s12272-013-0011-z.

PMID:
23325487
[PubMed - indexed for MEDLINE]
20.

Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.

Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey AK, Lewis A, Rades T, Prestidge CA.

Mol Pharm. 2009 May-Jun;6(3):861-72. doi: 10.1021/mp900063t.

PMID:
19358600
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk